Current Hematologic Malignancy Reports

, Volume 9, Issue 2, pp 165–173

Novel Antibody Therapy in Acute Lymphoblastic Leukemia


DOI: 10.1007/s11899-014-0202-9

Cite this article as:
Kochuparambil, S.T. & Litzow, M.R. Curr Hematol Malig Rep (2014) 9: 165. doi:10.1007/s11899-014-0202-9


The treatment of adult acute lymphoblastic leukemia (ALL) poses a tremendous challenge for hematologists. The use of pediatric-based chemotherapy regimens in young adults up to the age of 45 years has resulted in improved outcomes when compared retrospectively with historical controls treated with adult therapy. A better understanding of the molecular landscape of ALL and advances in the field of monoclonal antibody therapy have resulted in the development of several new agents that may provide for a reduction in the toxicity inherent in pediatric-like regimens. The anti-CD20 antibody, rituximab, anti CD22 antibody, epratuzumab, anti-CD22 antibody-drug conjugate, Inotuzumab ozogamicin, the bi-specific T-cell engager (BiTE) antibody, Blinatumomab, and chimeric receptor antigen (CAR) therapy are among the emerging agents that have demonstrated the potential to improve response rate and decrease toxicity when used alone or in combination with chemotherapy. Several role-defining phase II and phase III clinical trials with these agents are currently underway in the relapsed/refractory and newly diagnosed ALL settings.


Acute lymphoblastic leukemia Chemotherapy Monoclonal antibodies CD20 antibody Rituximab Anti-CD22 antibody Epratuzumab Inotuzumab ozogamicin Bi-specific T-cell engager (BiTE) antibody Blinatumomab Chimeric receptor antigen (CAR) therapy 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Division of HematologyMayo ClinicRochesterUSA

Personalised recommendations